News and resources | Resources
Video 7 March 2013

Introducing the study “Falsified medicines and the global public’s health”

By IFPMA
Share
Topics
Falsified medicinesTherapeutical products

David Taylor, Professor of Pharmaceutical and Public Health Policy, UCL School of Pharmacy

Geneva Pharma Forum: The Threat of False Friends Fake Medicines – Imminent Risks to Global Health to Global Health

About IFPMA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.

Learn more

Media Contact

Elliot Dunster

Related news and resources

Statement 6 Jun 2023

G20 side event on “Envisaging a Global R&D Network for Research in Vaccines, Therapeutics, and Diagnostics (VTDs) to enhance Prevention, Preparedness, and Response (PPR)”

On 6 June, IFPMA delivered a statement at the G20 “Strengthening Global Collaboration on Research and Development in MCMs (Diagnostics, Vaccines, and Therapeutics” side event on “Envisaging a Global R&D Network for Research in VTDs to enhance PPR” at the G20 3rd Health Working Group Meeting in Hyderabad.

Read more
Position paper 12 Apr 2023

Key considerations on the scope, utility and processes around updating the WHO Essential Medicines List

The WHO Essential Medicines List (EML) is an important tool in global health and supports the achievement of the UN Sustainable Development Goals. IFPMA has published perspectives from the R&D-based industry on the utility and scope of the EML. This position paper represents IFPMA's perspective as of April 2023, ahead of the publication of the revised version of the EML.

Read more
Statement 1 Feb 2023

Substandard and falsified medical products (EB152)

On 1 February 2023, IPSF submitted a statement delivered on behalf of IPSF, IAPO, and IFPMA for the WHO EB152 agenda item related to substandard and falsified medical products.

Read more
Top